Pharmaceuticals
Anti-HER2 Bispecific ADC JSKN003 Received Approval to Initiate a Phase III Clinical Study for the Treatment of HER2-positive Breast Cancer
SUZHOU, China, Feb. 6, 2025 /PRNewswire/ -- Alphamab Oncology (Stock Code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. ("CSPC") (Stock Code: 1093.HK) jointly announced that anti-HER2 biparatopic antibody-drug conjugate (ADC) JSKN003 has received approval from the Center for Drug Evaluation (...
2025-02-06 14:05
3675
Serplulimab Approved in the EU for First-Line Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
* Serplulimab is the world's first anti-PD-1 monoclonal antibody (mAb) approved for first-line treatment of ES-SCLC * Serplulimab is the first and only anti-PD-1 mAb approved in the European Union (EU) for the treatment of ES-SCLC * Serplulimab has now been approved in China, Europe, and sev...
2025-02-05 22:05
3714
LabConnect Announces Formation of Strategic Advisory Board and Appointment of Inaugural Members
JOHNSON CITY, Tenn., Feb. 4, 2025 /PRNewswire/ -- LabConnect, a leading provider of central lab services and functional service provider solutions, is proud to announce the formation of its Strategic Advisory Board and the appointment of its inaugural members. This board will further cement LabC...
2025-02-04 02:02
3020
Telix Completes Acquisition of Next-Generation Therapeutic Assets and Innovative Biologics Technology Platform
MELBOURNE, Australia and INDIANAPOLIS, Jan. 31, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces it has completed the acquisition from antibody engineering company ImaginAb, Inc. (ImaginAb). The acquisition includes a pipeline of next...
2025-01-31 06:01
4620
A Total of USD 12.7 Million Investment in New Diagnostics and Drug Development for NTDs and Malaria to Partners Including the Ohio State University, PATH, GSK and Others
TOKYO, Jan. 30, 2025 /PRNewswire/ -- The Global Health Innovative Technology (GHIT) Fund announced today a total investment of approximatelyJPY 2 billion ( USD 12.7 million1) in eight projects for the development of new diagnostics and drugs for neglected tropical diseases (NTDs) and malaria.2 J...
2025-01-30 10:00
3977
Asia Book of Records Honors Cipla (Emerging Markets & Europe business unit) for Record-Breaking Doctor engagement on COPD Awareness Initiative
Cipla's (EMEU BU) 'Take Charge – I Pledge' campaign engaged 4,350 doctors across six countries, setting a new benchmark in raising COPD awareness. MUMBAI, India, Jan. 29, 2025 /PRNewswire/ -- Cipla Limited (BSE: 500087) (NSE: CIPLA EQ) referred to as "Cipla" today announced that itsEmerging Marke...
2025-01-29 20:09
6379
Telix Completes Acquisition of RLS (USA) Inc.
MELBOURNE, Australia and INDIANAPOLIS, Jan. 28, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces it has completed the acquisition of RLS (USA) Inc. (RLS; RLS Radiopharmacies), America's only Joint Commission-accredited radiopharmacy n...
2025-01-28 05:40
7732
CARiNG Pharmacy Celebrates Consecutive Gold Triumph at the 2024 Putra Aria Brand Awards
KUALA LUMPUR, Malaysia, Jan. 27, 2025 /PRNewswire/ -- CARiNG Pharmacy is thrilled to announce its back-to-back victory in securing the Gold award in the retail category at the 2024 Putra Aria Brand Awards. This recognition highlights the brand's unwavering commitment to excellence in the retail ...
2025-01-27 08:33
3659
X4 Pharmaceuticals Announces EMA Validation of Marketing Authorization Application (MAA) for Mavorixafor - licenced to Norgine for commercialisation in Europe.
LONDON, Jan. 25, 2025 /PRNewswire/ -- Following the licensing agreement with X4 Pharmaceuticals, Norgine is pleased to see the announcement from X4 today that their Marketing Authorization Application (MAA) for mavorixafor for the treatment of WHIM syndrome (warts, hypogammaglobulinemia, infectio...
2025-01-25 02:00
6256
Kelun-Biotech's Product Tagitanlimab Approved for Marketing in Second Indication in Combination with Cisplatin and Gemcitabine For the First-line Treatment of Patients with recurrent or metastatic NPC
CHENGDU, China, Jan. 23, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that the Company received marketing authorization inChina from National Medical Products Administration (NMPA) for the programmed cell death ligand 1(PD-L1)-directed innovativ...
2025-01-23 13:44
3514
GC Cell Symposium with Bifarma Expands Global Impact and Reach for Immuncell-LC
YONGIN, South Korea, Jan. 23, 2025 /PRNewswire/ -- GC Cell
2025-01-23 09:30
2828
TraceLink Named to the 2025 RXinsider Pharmacy500 List for Excellence in Pharmacy Supply Chain Innovation
TraceLink recognized for advancing digitalization and orchestration in the pharmacy supply chain, ensuring safe and timely access to medications BOSTON, Jan. 22, 2025 /PRNewswire/ -- TraceLink, the largest end-to-end digital network platform for intelligent supply chain orchestration, is honored ...
2025-01-22 23:00
2721
JelloX Aims to Improve Patient-Centered Care with AI-powered 3D Digital Pathology
First shared at a recent Japanese Society of Digital Pathology meeting, the
company is forging a global alliance with a leading US medical institution and
other organizations to harness technology for better patient care and outcomes
in oncology.
TAIPEI, Jan. 22, 2025 /PRNewswire/ -- JelloX
2025-01-22 15:29
3273
Lepu Biopharma has granted ArriVent Exclusive License for MRG007, a Potential Best-in-Class ADC for the treatment of Gastrointestinal Cancers
HONG KONG, Jan. 22, 2025 /PRNewswire/ -- Today, Lepu Biopharma Co., Ltd (Stock Code: 02157.HK) announced that it has entered into an exclusive licensing agreement withArriVent BioPharma, Inc. for MRG007, a Potential Best-in-Class antibody- drug conjugate ("ADC") for the treatment of Gastrointesti...
2025-01-22 12:19
4520
Ascletis Announces Positive Results from U.S. Phase Ia Single Ascending Dose Study of Small Molecule Oral GLP-1R Agonist ASC30 and Provides Program Update
* ASC30 oral tablet demonstrated dose-proportional pharmacokinetic (PK) properties and a long half-life (t1/2) up to 60 hours in the single ascending dose (SAD) study of patients with obesity, supporting once-daily or less frequent oral dosing. * ASC30 oral tablet was generally safe and well ...
2025-01-21 19:00
4686
MedAdvisor Solutions' helps pharmacists in Australia deliver more than 115,000 clinical services to patients through Expanded Scope of Practice Pilots in 2024
New case study showcases improved operational efficiency and patient care with enhanced workflow and clinical services for pharmacists MELBOURNE, Australia, Jan. 21, 2025 /PRNewswire/ -- MedAdvisor Solutions, a global leader in patient engagement and pharmacy technology, published its newest cas...
2025-01-21 07:22
2588
SIRPAD - WORLD'S LARGEST RCT INVESTIGATING MAGICTOUCH PTA SIROLIMUS COATED BALLOON COMPLETES PATIENT ENROLMENT
TAMPA, Fla., Jan. 20, 2025 /PRNewswire/ -- Concept Medical Inc
2025-01-20 21:44
4330
Innovent and ASK Pharm Jointly Announce NMPA Approval of Limertinib, a Third-generation EGFR TKI for the Treatment of Lung Cancer
SAN FRANCISCO and SUZHOU, China, Jan. 17, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metaboli...
2025-01-17 08:00
5959
Innovent Presents at the 43rd Annual J.P. Morgan Healthcare Conference
Advancing into new stage of sustainable growth and global innovation SAN FRANCISCO and SUZHOU, China, Jan. 17, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines ...
2025-01-17 07:00
4707
Illuccix® Receives European Approval
MELBOURNE, Australia and LIÈGE, Belgium, Jan. 17, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that it has received a positive decision on the Marketing Authorization Application (MAA) for its prostate cancer PET[1] imaging agent ...
2025-01-17 06:14
4461
Week's Top Stories
Most Reposted
Edufrienz 99: One of Asia's First Digital Platform Advancing Character Education for Future-Ready, Compassionate Children
[Picked up by 316 media titles]
2026-01-23 11:03
UOB prices AUD2 billion in five-year senior unsecured notes
[Picked up by 305 media titles]
2026-01-23 09:00Agoda Launches Open-Source API Agent to Simplify MCP Server Integrations
[Picked up by 304 media titles]
2026-01-27 13:00
AVPN's AI Opportunity Fund Expands Regional Efforts to Build AI Skilling Infrastructure for a Future-Ready Workforce Across Asia-Pacific
[Picked up by 299 media titles]
2026-01-21 12:39Government of Telangana and Blaize Sign MoU at Davos to Launch Telangana AI Innovation Hub and Advance Applied AI Initiatives
[Picked up by 297 media titles]
2026-01-22 15:16
